GRI Bio, Inc. (GRI)
- Previous Close
0.4064 - Open
0.3950 - Bid --
- Ask 0.4011 x 100
- Day's Range
0.3950 - 0.4199 - 52 Week Range
0.3750 - 49.2800 - Volume
80,795 - Avg. Volume
299,852 - Market Cap (intraday)
1.304M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-28.2500 - Earnings Date May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 for the treatment of primary sclerosing cholangitis, and GRI-0729, which are in pre-clinical development. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
www.gribio.comRecent News: GRI
Performance Overview: GRI
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GRI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GRI
Valuation Measures
Market Cap
1.31M
Enterprise Value
-483.44k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.06
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-416.93%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-13.04M
Diluted EPS (ttm)
-28.2500
Balance Sheet and Cash Flow
Total Cash (mrq)
1.81M
Total Debt/Equity (mrq)
5.41%
Levered Free Cash Flow (ttm)
-5.2M
Research Analysis: GRI
Company Insights: GRI
GRI does not have Company Insights